Case report: Management of heterotopic ossification associated with
myocutaneous flap reconstruction of a sacral pressure ulcer
Colin W. McInnes1, Richard A.K. Reynolds2, Jugpal S. Arneja3 1Faculty of Medicine, University of British Columbia, Vancouver, BC2Department of Orthopedics, Children’s Hospital of Michigan, Detroit, MI3Division of Plastic Surgery, British Columbia Children’s Hospital, Vancouver, BC Background
Heterotopic ossification (HO) is a process whereby lamellar bone forms in the soft tissues HO has traditionally been a challenging diagnosis to successfully treat. Surgical excision has surrounding a joint, often following injury, such as trauma, burns, or arthroplasty.1,2,3 Clinically, been described as the treatment of choice for symptomatic HO although it comes with the patients can present with a decreased range of motion, pressure ulcers, nerve compression, associated risks of surgery.2,4 Due to high recurrence rates if surgical resection is performed swelling, pain, or asymptomatically. Symptomatic patients are most commonly treated with on an immature lesion, treatment is often delayed for months before operative intervention is surgical debridement of the affected heterotopic deposits.
performed for mature lesions.3 Another option is radiation treatment, which can be used for both therapeutic and prophylactic purposes in HO, but it also has common side effects.5-7 Spinal dysraphism (SD) is a term describing a wide range of congenital malformations of the neural tube. Many patients with SD have neuropathy below the affected neurologic level, Daily bisphosphonate therapy is believed to act through a combination of factors such as making them particularly susceptible to pressure ulcers. If these ulcers are severe and do not delaying apatite crystal aggregation, inhibiting calcium phosphate precipitation, and reducing respond to conservative therapy, they often require surgical debridement and flap the conversion of calcium phosphate into hydroxyapatite.8 It is likely that the aggressive PT, reconstruction, a clinical scenario that rarely results in HO. Herein we report a case history of a which has been used in patients with HO to improve range of motion and decrease patient with pelvic HO following myocutaneous flap reconstruction of a pressure ulcer who was recurrence8, had a synergistic effect with the bisphosphonate therapy.
successfully managed with oral bisphosphonate and aggressive physiotherapy (PT). Conclusion
Case Report
The outcome of this case suggests that non-surgical options for the treatment of established A 16-year-old Caucasian male with a diagnosis of spinal dysraphism at the L5 level presented HO are possible. Given the inherent risks of either surgery or radiation therapy, and considering with a 2 month history of a recurrent right ischial pressure ulcer. Computed tomography the low-risk nature of PT and bisphosphonate, the later may be suitable as an initial therapeutic confirmed right ischial osteomyelitis. The patient was treated with wide surgical debridement of option for symptomatic HO. We also hypothesize that combined PT and bisphosphonate soft tissue, ostectomy of the right ischial tuberosity, and right gluteus maximus myocutaneous therapy could also have a prophylactic role in patients at high risk for HO, such as those flap reconstruction. Three months post-operatively, the patient complained of limited hip mobility; a plain pelvis radiograph confirmed bilateral heterotopic ossification of the iliac crest to the femur (Figure 1). The patient was subsequently managed with a six-month course of References
aggressive physical therapy and oral bisphosphonate treatment (etidronate 20 mg/kg/day tid dosing), with significant clinical and radiographic improvement of bilateral hip range of motion 1. Venier LH, Ditunno JF,Jr. Heterotopic ossification in the paraplegic patient. Arch Phys Med Rehabil (Figure 2). Follow-up at 3 years post-therapy revealed no signs of recurrence. 1971;52:475-479. 2. Appelt EA, Kenkel JM, Ballard JR, Lopez JA, Anthony T, Castillo T. Preoperative embolization of heterotopic ossification for the treatment of a recalcitrant pressure sore. Plast Reconstr Surg 2005;116:50e-53e. 3. Gear AJ, Buckley C, Kaplan F, Vanbeek A. Multifactorial refractory heterotopic ossification. Ann Plast Surg 2004;52:319-324. 4. Chen HC, Yang JY, Chuang SS, Huang CY, Yang SY. Heterotopic ossification in burns: Our experience and literature reviews. Burns 2009;35:857-862. 5. Jang SH, Shin SW, Ahn SH, Cho IH, Kim SH. Radiation therapy for heterotopic ossification in a patient with traumatic brain injury. Yonsei Med J 2000;41:536-539. 6. Schaeffer MA, Sosner J. Heterotopic ossification: Treatment of established bone with radiation therapy. Arch Phys Med Rehabil 1995;76:284-286. 7. Vavken P, Castellani L, Sculco TP. Prophylaxis of heterotopic ossification of the hip: Systematic review and meta-analysis. Clin Orthop Relat Res 2009. [In press].
8. Ellerin BE, Helfet D, Parikh S, et al. Current therapy in the management of heterotopic ossification of the elbow: A review with case studies. Am J Phys Med Rehabil 1999;78:259-271. Figure 1. Pelvis radiograph showing large heterotopic ossification from the iliac crest to the femoral head (arrows) before commencing PT and bisphosphonate therapy.
Figure 2. Pelvis radiograph showing significant reduction of heterotopic ossification and correction of femur position in relation to the pelvis (arrows) 6 months after commencing aggressive PT and bisphosphonate therapy.


Propranolol and the risk of hospitalized myopathy: translating chemical genomics findings into population-level hypotheses

Propranolol and the risk of hospitalized myopathy:Translating chemical genomics findings intopopulation-level hypothesesSoko Setoguchi, MD, DrPH, a ,d John M. Higgins, MD, b,d,e Helen Mogun, MS, a Vamsi K. Mootha, MD, c andJerry Avorn, MD a Boston, MABackground A recent large-scale, chemical screening study raised the hypothesis that propranolol may increase the riskof myopathy. We tested this hy

Preliminary introduction to Infringement The rights conferred by a registered trade mark are set out in Article 5 of the TM Directive. Article 5 provides as follows: 1. The registered trade mark shall confer on the proprietor exclusive rights therein. The proprietor shall be entitled to prevent all third parties not having his consent from using in the course of trade: (a) any sign which is

Copyright © 2014 Medical Pdf Articles